Abstract
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
Highlights
Sriram Ravichandran 1, Steven Law 1, Shameem Mahmood1, Brenden Wisniowski1, Darren Foard1, Marianna Fontana1, Ana Martinez-Naharro1, Carol Whelan1, Julian D
TO THE EDITOR: Systemic Immunoglobulin light chain amyloidosis (AL) is a proteinmisfolding disorder associated with an underlying monoclonal B-cell or plasma cell dyscrasia
Whilst the prognosis of AL has markedly improved with novel agents [1], it remains incurable with a relapsing-remitting course, necessitating multiple treatment lines
Summary
Sriram Ravichandran 1, Steven Law 1, Shameem Mahmood1, Brenden Wisniowski1, Darren Foard1, Marianna Fontana1, Ana Martinez-Naharro1, Carol Whelan1, Julian D. Patients with primary refractory disease, those with ≤24 months follow up and continuing response and those who received 2nd line therapy for reasons other than progression are excluded from the analysis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
